These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 14999194)

  • 41. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
    Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A
    Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
    Stuckey TD; Stone GW; Cox DA; Tcheng JE; Garcia E; Carroll J; Guagliumi G; Rutherford BD; Griffin JJ; Turco M; Lansky AJ; Mehran R; Fahy M; Brodie BR; Grines CL;
    Am J Cardiol; 2005 Jan; 95(1):1-7. PubMed ID: 15619385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of abciximab with primary stenting in patients with acute myocardial infarction: a community hospital experience.
    Arjomand H; Mascarenhas DA
    J Invasive Cardiol; 2000 Mar; 12(3):125-9. PubMed ID: 10731278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).
    Nikolsky E; Grines CL; Cox DA; Garcia E; Tcheng JE; Sadeghi M; Mehran R; Lansky AJ; Na Y; Stone GW
    Am J Cardiol; 2007 Apr; 99(8):1055-61. PubMed ID: 17437727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
    Moliterno DJ; Yakubov SJ; DiBattiste PM; Herrmann HC; Stone GW; Macaya C; Neumann FJ; Ardissino D; Bassand JP; Borzi L; Yeung AC; Harris KA; Demopoulos LA; Topol EJ;
    Lancet; 2002 Aug; 360(9330):355-60. PubMed ID: 12241774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abciximab in coronary intervention for acute myocardial infarction and stable ischemic heart disease: early investment for growing benefit.
    Ferenczi EA; Malik IS; Mayet J; Foale RA; Francis DP
    J Invasive Cardiol; 2008 Sep; 20(9):437-41. PubMed ID: 18762671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
    Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
    J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
    Racine E
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.
    Neumann FJ; Kastrati A; Schmitt C; Blasini R; Hadamitzky M; Mehilli J; Gawaz M; Schleef M; Seyfarth M; Dirschinger J; Schömig A
    J Am Coll Cardiol; 2000 Mar; 35(4):915-21. PubMed ID: 10732888
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
    Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
    J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
    Roffi M; Moliterno DJ; Meier B; Powers ER; Grines CL; DiBattiste PM; Herrmann HC; Bertrand M; Harris KE; Demopoulos LA; Topol EJ;
    Circulation; 2002 Jun; 105(23):2730-6. PubMed ID: 12057986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Lansky AJ; Pietras C; Costa RA; Tsuchiya Y; Brodie BR; Cox DA; Aymong ED; Stuckey TD; Garcia E; Tcheng JE; Mehran R; Negoita M; Fahy M; Cristea E; Turco M; Leon MB; Grines CL; Stone GW
    Circulation; 2005 Apr; 111(13):1611-8. PubMed ID: 15811868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
    Lefkovits J; Ivanhoe RJ; Califf RM; Bergelson BA; Anderson KM; Stoner GL; Weisman HF; Topol EJ
    Am J Cardiol; 1996 May; 77(12):1045-51. PubMed ID: 8644655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB
    J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ; Topol EJ
    Am Heart J; 2000 Nov; 140(5):722-6. PubMed ID: 11054616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state.
    Kereiakes DJ
    Am J Cardiol; 1998 Apr; 81(7A):49E-54E. PubMed ID: 9551595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction--a meta-regression of randomized controlled trials.
    Sethi A; Bajaj A; Bahekar A; Bhuriya R; Singh M; Ahmed A; Khosla S
    Catheter Cardiovasc Interv; 2013 Aug; 82(2):171-81. PubMed ID: 22961908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
    Pannu R; Andraws R
    Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center.
    Zahn R; Fraiture B; Siegler KE; Schneider S; Gitt AK; Seidl K; Gandjour A; Wendland G; Vogt S; Lauterbach KW; Senges J
    Z Kardiol; 2003 Jun; 92(6):438-44. PubMed ID: 12819992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.